 Stacey Martiniano
Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 34 | 2023 | 955 | 8.320 |
Why?
| | Mycobacterium Infections, Nontuberculous | 16 | 2023 | 333 | 4.970 |
Why?
| | Nontuberculous Mycobacteria | 11 | 2023 | 204 | 3.420 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 5 | 2023 | 287 | 1.350 |
Why?
| | Mycobacterium avium-intracellulare Infection | 3 | 2021 | 63 | 1.310 |
Why?
| | Neonatal Screening | 4 | 2023 | 152 | 1.090 |
Why?
| | Ethambutol | 1 | 2021 | 20 | 0.750 |
Why?
| | Rifampin | 1 | 2021 | 68 | 0.730 |
Why?
| | Rhodospirillaceae | 1 | 2020 | 4 | 0.720 |
Why?
| | Azithromycin | 1 | 2021 | 80 | 0.720 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 231 | 0.710 |
Why?
| | Mycobacterium avium Complex | 3 | 2021 | 92 | 0.650 |
Why?
| | Respiratory Tract Diseases | 1 | 2020 | 138 | 0.640 |
Why?
| | Genetic Testing | 1 | 2021 | 379 | 0.630 |
Why?
| | Sputum | 3 | 2020 | 285 | 0.630 |
Why?
| | Algorithms | 2 | 2021 | 1466 | 0.580 |
Why?
| | Clofazimine | 1 | 2017 | 14 | 0.570 |
Why?
| | Coinfection | 4 | 2020 | 120 | 0.500 |
Why?
| | Mycobacterium abscessus | 3 | 2022 | 98 | 0.500 |
Why?
| | Humans | 36 | 2023 | 114623 | 0.460 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2014 | 112 | 0.420 |
Why?
| | Mutation | 5 | 2023 | 3344 | 0.420 |
Why?
| | Precision Medicine | 1 | 2016 | 336 | 0.410 |
Why?
| | Pneumonia | 1 | 2017 | 567 | 0.390 |
Why?
| | Retrospective Studies | 9 | 2022 | 12542 | 0.360 |
Why?
| | Microbial Sensitivity Tests | 3 | 2021 | 300 | 0.360 |
Why?
| | Disease Management | 1 | 2014 | 560 | 0.350 |
Why?
| | Lung Diseases | 1 | 2016 | 701 | 0.350 |
Why?
| | Infant, Newborn | 5 | 2023 | 5043 | 0.330 |
Why?
| | Aminophenols | 2 | 2022 | 112 | 0.310 |
Why?
| | Pseudomonas aeruginosa | 3 | 2021 | 298 | 0.290 |
Why?
| | Morbidity | 2 | 2019 | 280 | 0.270 |
Why?
| | Child | 8 | 2022 | 18404 | 0.260 |
Why?
| | Infant | 5 | 2023 | 7959 | 0.220 |
Why?
| | Adolescent | 7 | 2021 | 17831 | 0.210 |
Why?
| | Leprostatic Agents | 1 | 2022 | 3 | 0.210 |
Why?
| | Quality Improvement | 3 | 2020 | 950 | 0.210 |
Why?
| | Delayed Diagnosis | 1 | 2023 | 70 | 0.210 |
Why?
| | Cohort Studies | 4 | 2022 | 4894 | 0.200 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 9 | 0.200 |
Why?
| | Trypsinogen | 1 | 2021 | 9 | 0.190 |
Why?
| | Antibiotics, Antitubercular | 1 | 2021 | 34 | 0.190 |
Why?
| | Oropharynx | 1 | 2021 | 36 | 0.190 |
Why?
| | Bacteriophages | 1 | 2022 | 75 | 0.180 |
Why?
| | Symptom Flare Up | 1 | 2020 | 38 | 0.180 |
Why?
| | Specimen Handling | 1 | 2021 | 155 | 0.170 |
Why?
| | Drug Therapy, Combination | 1 | 2022 | 951 | 0.170 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 268 | 0.170 |
Why?
| | Antitubercular Agents | 1 | 2021 | 169 | 0.170 |
Why?
| | Data Interpretation, Statistical | 1 | 2021 | 321 | 0.170 |
Why?
| | Cross-Over Studies | 1 | 2021 | 440 | 0.170 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 87 | 0.160 |
Why?
| | Respiratory Function Tests | 1 | 2020 | 522 | 0.160 |
Why?
| | Infection Control | 1 | 2019 | 135 | 0.150 |
Why?
| | Risk Factors | 4 | 2019 | 8628 | 0.150 |
Why?
| | United States | 5 | 2021 | 12176 | 0.150 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1477 | 0.150 |
Why?
| | Cross Infection | 1 | 2019 | 197 | 0.150 |
Why?
| | Anticoagulants | 1 | 2021 | 550 | 0.140 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 1691 | 0.140 |
Why?
| | Lipopolysaccharides | 1 | 2020 | 821 | 0.140 |
Why?
| | Radiography, Thoracic | 1 | 2017 | 150 | 0.130 |
Why?
| | Anti-Infective Agents | 1 | 2019 | 225 | 0.130 |
Why?
| | Chloride Channel Agonists | 1 | 2016 | 62 | 0.130 |
Why?
| | Treatment Outcome | 3 | 2019 | 9084 | 0.130 |
Why?
| | Respiratory Tract Infections | 1 | 2019 | 319 | 0.120 |
Why?
| | Quinolones | 1 | 2016 | 97 | 0.120 |
Why?
| | Genetic Therapy | 1 | 2016 | 257 | 0.120 |
Why?
| | Young Adult | 4 | 2020 | 10455 | 0.120 |
Why?
| | Genotyping Techniques | 1 | 2014 | 69 | 0.110 |
Why?
| | Registries | 1 | 2021 | 1767 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 447 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 931 | 0.110 |
Why?
| | Global Health | 1 | 2015 | 287 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2020 | 3003 | 0.110 |
Why?
| | Decision Making | 1 | 2019 | 782 | 0.110 |
Why?
| | Genetic Markers | 1 | 2014 | 320 | 0.110 |
Why?
| | Child, Preschool | 3 | 2021 | 9108 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 372 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 1842 | 0.110 |
Why?
| | Prevalence | 1 | 2019 | 2249 | 0.100 |
Why?
| | Male | 7 | 2022 | 55554 | 0.100 |
Why?
| | Neutrophil Activation | 1 | 2013 | 94 | 0.100 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 61 | 0.100 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 475 | 0.100 |
Why?
| | Pseudomonas Infections | 1 | 2014 | 184 | 0.100 |
Why?
| | Mycobacterium | 1 | 2013 | 103 | 0.100 |
Why?
| | Genotype | 1 | 2016 | 1760 | 0.090 |
Why?
| | Female | 6 | 2021 | 59466 | 0.090 |
Why?
| | Metagenomics | 2 | 2021 | 131 | 0.090 |
Why?
| | Prospective Studies | 1 | 2021 | 6217 | 0.090 |
Why?
| | Disease Progression | 1 | 2016 | 2380 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4411 | 0.080 |
Why?
| | Adult | 4 | 2020 | 30528 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2021 | 2094 | 0.070 |
Why?
| | Animals | 2 | 2019 | 31694 | 0.070 |
Why?
| | Genomics | 2 | 2021 | 635 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6344 | 0.070 |
Why?
| | Lung | 3 | 2022 | 3558 | 0.060 |
Why?
| | Mycobacterium avium | 1 | 2023 | 21 | 0.050 |
Why?
| | Aspergillus fumigatus | 1 | 2021 | 20 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2023 | 246 | 0.050 |
Why?
| | Middle Aged | 2 | 2020 | 26719 | 0.050 |
Why?
| | Complement System Proteins | 1 | 2023 | 282 | 0.040 |
Why?
| | Aged | 1 | 2017 | 19061 | 0.040 |
Why?
| | Neutrophils | 1 | 2023 | 1176 | 0.040 |
Why?
| | Pilot Projects | 1 | 2020 | 1372 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 1796 | 0.030 |
Why?
| | Superoxides | 1 | 2013 | 214 | 0.030 |
Why?
| | Incidence | 1 | 2017 | 2311 | 0.020 |
Why?
| | Biofilms | 1 | 2013 | 223 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 3408 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1518 | 0.020 |
Why?
|
|
Martiniano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|